Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays

BACKGROUND: A challenge for drug of abuse testing is presented by ‘designer drugs’, compounds typically discovered by modifications of existing clinical drug classes such as amphetamines and cannabinoids. Drug of abuse screening immunoassays directed at amphetamine or methamphetamine only detect a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasowski, Matthew D, Ekins, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029917/
https://www.ncbi.nlm.nih.gov/pubmed/24851137
http://dx.doi.org/10.1186/1758-2946-6-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029917/
https://www.ncbi.nlm.nih.gov/pubmed/24851137
http://dx.doi.org/10.1186/1758-2946-6-22

Ejemplares similares